Effects of Interleukin-1β Inhibition on Incident Anemia: Exploratory Analyses From a Randomized Trial

Analysis of data from CANTOS study shows during a median follow-up of 3.7yrs, participants without baseline anaemia(n=8,683) who received canakinumab at any dosage had significantly less incident anaemia than those who received placebo (HR 0.84 [95% CI, 0.77 to 0.93], P<0.001)


Annals of Internal Medicine